The use of quantitative real-time polymerase chain reaction (qRT-PCR) to test for BCR-ABL1 transcript levels in chronic myeloid leukemia (CML) is t......READ MORE
Chronic myeloid leukemia (CML) is often assessed by using conventional models that predate the introduction of tyrosine kinase inhibitor (TKI) ther......READ MORE
For some—but not all—patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy produces deep remissions with immune res......READ MORE
by Gabriela S. Hobbs, MD; Mark J. Levis, MD, PhD; and Neil P. Shah, MD, PhD
Current systems to predict risk in patients with chronic myeloid leukemia (CML) are based on clinical parameters to guide treatment, although there......READ MORE
by Gabriela S. Hobbs, MD; Mark J. Levis, MD, PhD; and Neil P. Shah, MD, PhD
Current guidelines identify the goals of chronic myeloid leukemia (CML) treatment, with an emphasis on the achievement of a stable deep molecular r......READ MORE
In addition to the chronic myeloid leukemia (CML) risk category, the choice of a particular tyrosine kinase inhibitor (TKI) therapy for initial tre......READ MORE
